Solitron Devices, Inc. filings document operating results, bookings disclosures and governance matters for a manufacturer of solid state semiconductor components and related devices serving military and aerospace markets. Current reports on Form 8-K furnish press releases on fiscal results, bookings, backlog, Regulation FD disclosures, and material events connected to the company’s operations.
Proxy materials cover annual-meeting matters including Class III director elections, auditor ratification and advisory votes on executive compensation. The filing record also reflects disclosure topics tied to the Micro Engineering Inc. acquisition, including integration-related reporting, acquisition accounting, contingent consideration, capital-structure disclosures and board governance.
Olesen Value Fund L.P., together with Olesen Value Fund GP LLC and Christian Olesen, reports beneficial ownership of 216,508 Solitron Devices Inc. common shares, representing approximately 10.1% of the company’s outstanding stock, based on 2,152,703 shares outstanding as of July 10, 2026.
The position, acquired in open‑market transactions for an aggregate purchase price of approximately $811,460 using the fund’s working capital, is held for investment purposes in margin accounts. Olesen Value Fund has sole voting and dispositive power; the GP entity and Christian Olesen share such powers indirectly and disclaim beneficial ownership for other purposes. In the 60 days before July 21, 2026, Olesen Value Fund executed multiple open‑market sales of Solitron Devices shares, including 5,238 shares at $26.60 on June 24, 2026 and 3,366 shares at $29.71 on July 20, 2026. The reporting group states an interest in discussing options for shareholder value creation with Solitron’s management, board, or third parties and may adjust its holdings over time.
Solitron Devices Inc. shareholder Olesen Value Fund L.P., a 10% owner, and related entities reported open-market sales of 24,204 shares of common stock on July 17, 20 and 21, 2026 at prices between $29.56 and $29.82 per share. The filing is joint, and each reporting person disclaims beneficial ownership beyond its pecuniary interest.
Solitron Devices, Inc. reported strong unaudited results for the fiscal 2027 first quarter ended May 31, 2026. Net sales were $5.44 million, up from $2.70 million a year earlier, driving a swing from a net loss of $0.34 million to net income of $0.99 million, or $0.46 per share, compared with a loss of $0.16 per share. Gross profit rose to $2.47 million from $0.39 million, and operating income improved to $1.54 million from a loss of $0.38 million.
Cash and cash equivalents increased to $6.04 million from $3.91 million at February 28, 2026, and total assets were $27.58 million with stockholders’ equity of $20.90 million. Backlog was $23.34 million at quarter-end versus $27.28 million at the beginning of the fiscal year, but a $5.04 million MEI order received after quarter-end brought backlog to $26.97 million as of July 2026. The company highlighted potential demand from a U.S. Air Force request to double AMRAAM missile production by 2028 and noted ongoing exploration of strategic alternatives with an investment banker.
Solitron Devices, Inc. reported a strong turnaround for the three months ended May 31, 2026. Net sales were $5,436,000, up 101% from $2,700,000 a year earlier, driven by higher backlog and scheduled deliveries. Gross profit rose to $2,465,000, with gross margin improving to 45% from 14%.
Operating income was $1,535,000 versus a prior-year operating loss of $378,000. Net income reached $990,000, compared with a net loss of $336,000, and basic and diluted EPS were $0.46. Operating cash flow was $2,171,000, lifting cash and cash equivalents to $6,036,000 and working capital to $10,812,000.
Backlog at May 31, 2026 was $23,341,000, up 28% year over year, although net bookings for the quarter declined 48%. The contingent consideration liability related to the MEI acquisition increased to $1,119,000 due to higher MEI backlog. Management notes a previously identified material weakness in internal control over financial reporting remains, as new controls had not operated long enough to demonstrate effectiveness.
Olesen Value Fund L.P., a more than ten percent holder of Solitron Devices Inc. (SODI), reported open-market sales of common stock on July 8 and July 10 at prices of $26.85 and $26.54 per share, respectively. After these transactions, the Reporting Persons collectively report 222,931 shares of common stock, with ownership held directly by the fund and indirectly through related entities, each disclaiming beneficial ownership beyond its pecuniary interest.
Olesen Value Fund L.P., a ten percent owner of Solitron Devices Inc, reported a series of open-market sales of common stock. Across July 1–7, 2026, entities associated with the fund sold a total of 13,488 shares at prices ranging from $26.24 to $26.83 per share.
Following these transactions, the reporting group shows 226,298 shares of Solitron Devices common stock beneficially owned. The shares are held directly by Olesen Value Fund L.P. and indirectly through related entities and Christian Olesen, each of whom disclaims beneficial ownership beyond their pecuniary interest.
Olesen Value Fund L.P. and related entities reported open-market sales of Solitron Devices Inc. common stock, totaling 27,352 shares, in late June 2026. The sales were executed at prices around $26.59–$26.60 per share.
After these transactions, the filing shows combined holdings of 229,670 shares of Solitron Devices common stock. Footnotes state that Olesen Value Fund L.P., its general partner, its investment manager, and Christian Olesen are joint reporting persons and each disclaims beneficial ownership except to the extent of any pecuniary interest.
SODI proposed the sale of 20,000 shares of Common Stock, $0.01 par value, via a Section 144 notice dated 06/24/2026. The shares are listed OTC-PINK and were acquired in open-market purchases beginning 10/16/2015 with cash settlement beginning 10/22/2015.
The filing names Auerbach Grayson & Company LLC as the broker and records payment as "cash payment of good funds upon regular trade settlement". The notice describes planned resale method as open-market transactions; timing and proceeds recipients are not detailed in the excerpt.
SOLITRON DEVICES INC director and CEO Howard Timothy Eriksen reported an internal restructuring of his Solitron share holdings. On June 5, 2026, 5,787 shares of common stock were moved from an indirect entity to his direct ownership at a reported price of $0.00 per share, with no open-market buying or selling.
Following these transactions, Eriksen directly holds 60,827 shares of common stock and is also reported as indirectly associated with 264,396 shares held through investment entities and managed accounts. Footnotes state that he may be deemed to beneficially own these indirect holdings but disclaims beneficial ownership beyond his pecuniary interest.
Solitron Devices, Inc. reports higher full-year results for the fiscal year ended February 28, 2026, driven by strong defense and aerospace demand. Net sales rose about 21% to $16.97 million from $14.05 million, lifting gross profit to $5.12 million and margin to 30%.
Backlog expanded sharply to $27.28 million, about 51% above the prior year, supported by a significant AMRAAM program order and a book-to-bill ratio of roughly 1.54 to 1. Despite higher operating income, net income was essentially flat at $0.81 million due to contingent consideration tied to the Micro Engineering Inc. acquisition and investment mark-to-market losses.
The business remains highly concentrated, with ConMed Linvatec and RTX Corporation representing 33% and 27% of 2026 net sales, and nine customers providing 91% of revenue. Cash and equivalents were $3.91 million at year-end, with working capital of $9.03 million, and management believes existing liquidity is sufficient for at least the next twelve months.